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CASE REPORT
A Permanent Hair Loss in a Patient with 
Hypersensitivity to Intralesional Triamcinolone Injection
Young In Lee, Minseok Lee, Sewon Lee1, Do Young Kim
Department of Dermatology and Cutaneous Biology Research Institute, Yonsei University College of Medicine, 1Yonsei Leeand Skin Clinic, 
Seoul, Korea
Despite multiple possible side effects, mesotherapy with a di-
verse mixture of unapproved products has been performed 
for the treatment of hair loss. In this case report, we present 
a rare case of permanent hair loss due to an allergic reaction 
from a mesotherapy mixture including triamcinolone 
acetonide. The patient showed a positive intradermal aller-
gic skin test result for triamcinolone and therefore was diag-
nosed with scarring alopecia due to delayed type IV hyper-
sensitivity to corticosteroid. This case study suggests that der-
matologists should always be fully aware that both IgE-medi-
ated and non-IgE-mediated hypersensitivity reactions from 
the corticosteroids as well as their mesotherapy excipients 
are possible in an effort to prevent irreversible adverse event 
from the mesotherapy. (Ann Dermatol 31(2) 217∼220, 2019)
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INTRODUCTION
Mesotherapy has been widely applied in the treatment of 
alopecia, despite the lack of data regarding its potential 
adverse effects. Here, we present a case of permanent hair 
loss on injection sites due to a delayed type IV hyper-
sensitivity reaction from a mesotherapy mixture that in-
cludes triamcinolone acetonide. This report highlights the 
possible risk of mesotherapy as a treatment modality for 
hair loss. 
CASE REPORT
A 26-year-old woman with a history of female pattern alo-
pecia presented to the dermatology clinic with edema, er-
ythema, and numbness on her entire face after her first in-
tralesional injection on the scalp of a mesotherapy mixture 
at a private clinic (Fig. 1). She was healthy with no past 
medical history or atopic disease. According to her medi-
cal records from the clinic, a painful edema and redness 
on her forehead developed on the day after the injection 
and later extended downward to her entire face. Edema 
and pain persisted for more than a week, and finally atro-
phic scars with crusts were formed at each injection site 
(Fig. 2). An intradermal allergic skin test for possible culprit 
agents was performed, and a positive reaction to 0.25 ml 
triamcinolone acetonide (Dongkwang Pharm, Seoul, Korea) 
at the concentration of 10 mg/ml after 24 hours was iden-
tified (Fig. 3). The patient was diagnosed with alopecia 
due to a delayed hypersensitivity reaction to intralesional 
triamcinolone acetonide injection. Our clinic prescribed 
treatment with 3% topical minoxidil and intermittent 
non-ablative fractional laser therapy for the regeneration of 
the scalp dermis, but no sufficient improvement was 
noticed. We received the patient’s consent form about 
publishing all photographic materials.
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Fig. 1. Initial photographs of hyper-
sensitivity reaction. Swelling on (A) 
face and (B) scalp developed after 
intralesional injection of the meso-
therapy mixture.
Fig. 2. A permanent hair loss shown at each intralesional corti-
costeroid injection site 1 month after the injection.
Fig. 3. Intradermal allergic skin test results showed positive re-
action to 10 mg/ml triamcinolone acetonide: A, 100,000:1 mix-
ture of 2% lidocaine+epinephrine; B, 2:1 mixture of normal 
saline+NaHCO3; C, normal saline (0.9% sodium chloride); D, 
antibiotics (lincomycin); E, 8:1 mixture of normal saline+10 
mg/ml triamcinolone acetonide; F, 5 mg/ml dexamethasone. 
DISCUSSION
In contrast to the extremely frequent application of corti-
costeroids in many dermatologic diseases, the reported in-
cidence of allergic reactions to these compounds is rela-
tively uncommon1. Recently, however, the adverse events 
from the use of corticosteroids are increasingly recognized 
worldwide as a problem with considerable clinical import-
ance. Both type I and type IV hypersensitivity reactions 
have been reported following exposure to corticosteroids2. 
Especially, the allergic contact dermatitis after the topical 
application of corticosteroids is the most commonly ob-
served hypersensitivity reaction, occurring in 4%∼5% of 
the population3.
Corticosteroids are also known to cause sensitization 
when used systemically, albeit this mode of sensitization 
is much more rare4. The prevalence of IgE-mediated, type 
I hypersensitivity reactions to systemic corticosteroids is 
reported to be approximately 0.3%5. One of the earliest 
reports of the immediate type I reaction to systemic corti-
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costeroids described urticaria, angioedema, and broncho-
spasm after injections of corticosteroids in 20 of 2,256 pa-
tients6.
A type IV hypersensitivity reaction to systemic and intrale-
sional steroids presents typically as a generalized dermati-
tis or an exanthematous eruption, occasionally with blis-
ters and purpuras7. Bircher et al.8 reported a delayed hy-
persensitivity to the oral administration of prednisone, in-
ducing a generalized exanthem in the patient. Räsänen 
and Hasan3 also documented delayed hypersensitivity re-
actions to oral or intralesional corticosteroids in five pa-
tients, who developed diffuse erythema in a few to 24 hours 
after patch or intradermal skin tests.
There are 5 classes of structurally distinct corticosteroids, 
termed as class A, B, C, D1, and D29,10. These groups 
were defined according to substitutions on the cortico-
steroid structure and clinical characteristics. However, less 
is known about the classification and cross-reactivity pat-
tern of the less common reactions following systemic ad-
ministration of corticosteroids11. Our patient developed 
marked edema and erythema a few hours after the intrale-
sional injection of triamcinolone acetonide, which belongs 
to the class B corticosteroids. We performed an allergic in-
tradermal skin test for suspected drugs, including triam-
cinolone, the excipients (100,000:1 mixture of 2% lido-
caine/epinephrine, sodium bicarbonate, and 0.9% sodium 
chloride), antibiotics (lincomycin), and dexamethasone. After 
24 hours, the patient presented with a positive intradermal 
skin test result solely at the triamcinolone site. Although a 
strong positive reaction to triamcinolone was noted, the 
intradermal skin test for dexamethasone, which belongs to 
the class C corticosteroids, was negative. This result sup-
ports the recent study on reaction patterns to corticoste-
roids, which indicated that reactivity to only one type of 
corticosteroid is much more common than reactivity to 
multiple types12. Therefore, even though a patient reports 
no adverse events with previous steroid use, a dermatolo-
gist should still consider the possibility that the patient 
may undergo a hypersensitivity reaction to other types of 
steroids.
Several previous reports on triamcinolone acetonide hy-
persensitivity have reported that the culprit agent could be 
not only the corticosteroid itself but also its excipients, 
such as carboxymethylcellulose, benzyl alcohol, and poly-
sorbate 8013-15. As the limitation to our study, we did not 
extensively analyze the excipients added to the triamcin-
olone mesotherapy mixture. It is crucial to perform aller-
gologic testing of individual pharmaceutical excipients as 
well, since allergic reactions are not purely caused by the 
active pharmaceutical constituents.
In conclusion, our report presents a rare case of perma-
nent hair loss following a severe type IV delayed hyper-
sensitivity reaction to intralesional triamcinolone aceto-
nide as part of a mesotherapy mixture. Although multiple 
side effects have been reported, mesotherapy with a di-
verse mixture of unapproved products has gained popular-
ity for the treatment of alopecia16. To prevent irreversible 
side effects, physicians should always be fully aware that 
both IgE-mediated and non-IgE-mediated hypersensitivity 
reactions from the corticosteroids or their mesotherapy 
mixtures are possible. Especially, patients with atopic dis-
ease or previous history of drug allergy should be consid-
ered for testing to the corticosteroid as well as the ex-
cipients, because patterns of hypersensitivity reactions to 
mesotherapy are not fully uncovered at this point. 
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